Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsITGDF 72 Debt-to-Equity is 0.89 as of Dec. 2025, which is 9% below its 10-year median of 0.98. GuruFocus rates ITGDF with a GF Score™ of 72/100 and a GF Value™ of $1.17 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 80.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Integral Diagnostics's Debt-to-Equity or its related term are showing as below:
ITGDF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.7 Med: 0.98 Max: 1.31
Current: 0.89
During the past 10 years, the highest Debt-to-Equity Ratio of Integral Diagnostics was 1.31. The lowest was 0.70. And the median was 0.98.
ITGDF's Debt-to-Equity is ranked worse than 80.22% of 182
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs ITGDF: 0.89
Integral Diagnostics (OTCPK:ITGDF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Integral Diagnostics Debt-to-Equity Related Terms
Integral Diagnostics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITGDF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ITGDF) has a Debt-to-Equity of 0.89 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Integral Diagnostics and its competitors. This is near median its historical median of 0.98. Over the past decade, Integral Diagnostics' Debt-to-Equity has ranged from 0.70 to 1.31. According to the industry distribution chart, Integral Diagnostics ranks #146 out of 182 companies in the Medical Diagnostics & Research industry, placing it in the top 80.2%.
Is Integral Diagnostics' Debt-to-Equity too high?
Integral Diagnostics' current Debt-to-Equity of 0.89 is near median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 1.31. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Integral Diagnostics' value of 0.89 is 169.7% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #146 out of 182 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integral Diagnostics has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #146 out of 182 companies for Debt-to-Equity. This places Integral Diagnostics in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Integral Diagnostics' value of 0.89 is 169.7% above this benchmark. Historically, Integral Diagnostics' own Debt-to-Equity has ranged from 0.70 to 1.31 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 0.33, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Debt-to-Equity of 0.89 is 169.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Debt-to-Equity is 0.89, which is near median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $2.61 — trading 123.3% above its estimated fair value. The current Debt-to-Equity is 0.89, which is near median its 10-year median of 0.98 and 169.7% above the Medical Diagnostics & Research industry median of 0.33. Integral Diagnostics' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current Debt-to-Equity is 0.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be overvalued.
The current stock price of $2.61 is trading 123.3% above its estimated GF Value™ of $1.17.
GuruFocus considers Integral Diagnostics to be Significantly Overvalued.
Key valuation signals for ITGDF:
Debt-to-Equity: 0.89 (near median its 10-year median of 0.98)
GF Value™: $1.17 vs. price of $2.61 (123.3% above fair value)
Industry Position: 169.7% above the Medical Diagnostics & Research median (#146 of 182)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
72GF Score
Get the complete analysis for ITGDF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 
